[gtrans]
You Are Here: Home » About » Finance and Funding

Finance and Funding

Funding Statement

EFNA funding arises from a small number of sources, including the pharmaceutical and medical device industries, the European Commission and others. Some of the grants are specific for particular EFNA projects and, where possible, we try to involve a consortium of donors for each project.

No donor, including the European Commission, has had any undue influence of any kind over EFNA’s activities, nor are there any conflicts of interest.

It is important to remember that EFNA is an extremely broadly-based organisation, which attempts to improve the quality of life for people in Europe living with neurological illness. Our projects are equally broad and tend to deal with issues generic to all or several neurological conditions and education rather than with specific drugs or other treatments. EFNA’s relationships within the pharmaceutical and medical device industry are usually at the level of government affairs and policy and our relationships with all sponsors/funders are regulated carefully by our “Code of Practice”.

ACKNOWLEDGEMENT OF FINANCIAL SUPPORT

EFNA would like to acknowledge support from Industry in 2015:

PFIZER

NOVARTIS

ALLERGAN

BIOGEN

ROCHE

MSD

AMGEN

GRUNENTHAL

45.732.51 €

30.000 €

35.000 €

20.000 €

20.000 €

15.000 €

10.000 €

22.000 €

 
 

We are also very grateful to our neurologist colleagues at the European Academy of Neurology (scientific/non-industry support) for their contribution for 20,000euros in 2015.

In 2015, the % of the highest contribution from a single company was approximately 21% from Pfizer (45.732.51euros)
89% of income in 2015 was raised from grants/sponsorship from industry vs. 11% from our health professional partner and other sources.
 

EFNA is registered in Belgium as an Association Sans But Lucratif (ASBL) #0543319269 | Website by www.bizify.ie

Scroll to top